Biointron Launches RushData Platform for AI-Driven Antibody Discovery
Biointron has introduced RushData, an integrated high-throughput platform designed to accelerate AI-driven antibody discovery. The system aims to significantly reduce the time required for data generation and analysis in the antibody development process.
Biointron has unveiled its new RushData platform, engineered to expedite AI-assisted antibody discovery. The platform's objective is to substantially shorten the timeframe for high-throughput data generation and analysis within antibody development.
RushData enables CHO expression within a single day, yielding data in days rather than weeks. This process generates standardized, structured datasets prepared for AI and machine learning algorithms. The platform also supports custom workflows for various targets and modalities, capable of processing over 3,000 molecules in parallel per batch.
The company highlights that the platform assists in early identification of developability liabilities through assessment protocols. This facilitates a faster and more efficient discovery and development cycle for antibodies, a critical aspect of the pharmaceutical industry.
RushData's integrated approach combines data collection, analysis, and AI-based design, aiming to streamline the entire antibody discovery pipeline. This is expected to accelerate the introduction of new therapeutic antibodies to the market.